Super responders to guselkumab treatment in moderate‐to‐severe psoriasis: a real clinical practice pilot series

• Published in: International journal of dermatology Vol. 61; no. 8; pp. 1029 - 1033
• Main Authors: Ruiz‐Villaverde, Ricardo, Rodriguez‐Fernandez‐Freire, Lourdes, Armario‐Hita, Jose C., Pérez‐Gil, Amalia, Galán‐Gutiérrez, Manuel
• Format: Journal Article
• Language: English
• Published: Hoboken Blackwell Publishing Ltd 01-08-2022
• Subjects: Clinical medicine; Evaluation; Optimization; Patients; Pruritus; Psoriasis; Skin diseases; Statistical analysis; Survival
• ISSN: 0011-9059; 1365-4632
• DOI: 10.1111/ijd.15784

Background
The term super responders defines a subset of patients with moderate‐to‐severe psoriasis that present a rapid and higher rate of response to biological treatments in comparison to the general population. Little scientific evidence to explain the behavior and clinical characteristics of these psoriatic patients has been published thus far. Its characterization could be important to improve therapeutic optimization and to identify the profile of patients that will respond efficiently to biological treatments.
Objectives
The main objective of this study was to evaluate and characterize the proportion of super‐responder patients (who achieved PASI = 0 at week 12 and 24) in a total of 87 patients with moderate‐to‐severe psoriasis treated with guselkumab. Also, our intent was to analyze and evaluate differences in response to guselkumab in absolute PASI, PASI 75, PASI 90, PASI 100, BSA, VAS pruritus, and DLQI between groups.
Results
A total of 14 out of 87 patients treated with guselkumab were characterized as SR. No differences in demographic characteristics were found. The percentage of patients reaching PASI 75, PASI 90, and PASI 100 were numerically greater for SR than N‐SR at week 12, 24, 36, and 52. These differences were more pronounced for PASI 100 > PASI 90 > PASI 75. SR performed better and faster to guselkumab treatment as assessed by absolute PASI, BSA, VAS pruritus, and DLQI. Statistically significant differences were found in absolute PASI, BSA, VAS pruritus, and DLQI between groups along the 52 weeks of study. No differences in drug survival were found between groups (P = 0.3326).
Conclusion
Our study demonstrated for the first time, in a real clinical practice setting, the presence of a subpopulation of patients that super respond to guselkumab at week 12 and 24 and maintain this efficacy for 52 weeks. Further research must be performed to identify basal specific characteristics of this SR population.